The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa : Results of a prospective European cohort study. / van Straalen, Kelsey R.; Tzellos, Thrasyvoulos; Guillem, Phillipe; Benhadou, Farida; Cuenca-Barrales, Carlos; Daxhelet, Mathilde; Daoud, Mathieu; Efthymiou, Ourania; Giamarellos-Bourboulis, Evangelos J.; Jemec, Gregor B.E.; Katoulis, Alexandros C.; Koenig, Anke; Lazaridou, Elizabeth; Marzano, Angelo V.; Matusiak, Łucas; Molina-Leyva, Alejandro; Moltrasio, Chiara; Pinter, Andreas; Potenza, Concetta; Romaní, Jorge; Saunte, Ditte M.; Skroza, Nevena; Stergianou, Dimitra; Szepietowski, Jacek; Trigoni, Anastasia; Vilarrasa, Eva; van der Zee, Hessel H.

I: Journal of the American Academy of Dermatology, Bind 85, Nr. 2, 2021, s. 369-378.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

van Straalen, KR, Tzellos, T, Guillem, P, Benhadou, F, Cuenca-Barrales, C, Daxhelet, M, Daoud, M, Efthymiou, O, Giamarellos-Bourboulis, EJ, Jemec, GBE, Katoulis, AC, Koenig, A, Lazaridou, E, Marzano, AV, Matusiak, Ł, Molina-Leyva, A, Moltrasio, C, Pinter, A, Potenza, C, Romaní, J, Saunte, DM, Skroza, N, Stergianou, D, Szepietowski, J, Trigoni, A, Vilarrasa, E & van der Zee, HH 2021, 'The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study', Journal of the American Academy of Dermatology, bind 85, nr. 2, s. 369-378. https://doi.org/10.1016/j.jaad.2020.12.089

APA

van Straalen, K. R., Tzellos, T., Guillem, P., Benhadou, F., Cuenca-Barrales, C., Daxhelet, M., Daoud, M., Efthymiou, O., Giamarellos-Bourboulis, E. J., Jemec, G. B. E., Katoulis, A. C., Koenig, A., Lazaridou, E., Marzano, A. V., Matusiak, Ł., Molina-Leyva, A., Moltrasio, C., Pinter, A., Potenza, C., ... van der Zee, H. H. (2021). The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study. Journal of the American Academy of Dermatology, 85(2), 369-378. https://doi.org/10.1016/j.jaad.2020.12.089

Vancouver

van Straalen KR, Tzellos T, Guillem P, Benhadou F, Cuenca-Barrales C, Daxhelet M o.a. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study. Journal of the American Academy of Dermatology. 2021;85(2):369-378. https://doi.org/10.1016/j.jaad.2020.12.089

Author

van Straalen, Kelsey R. ; Tzellos, Thrasyvoulos ; Guillem, Phillipe ; Benhadou, Farida ; Cuenca-Barrales, Carlos ; Daxhelet, Mathilde ; Daoud, Mathieu ; Efthymiou, Ourania ; Giamarellos-Bourboulis, Evangelos J. ; Jemec, Gregor B.E. ; Katoulis, Alexandros C. ; Koenig, Anke ; Lazaridou, Elizabeth ; Marzano, Angelo V. ; Matusiak, Łucas ; Molina-Leyva, Alejandro ; Moltrasio, Chiara ; Pinter, Andreas ; Potenza, Concetta ; Romaní, Jorge ; Saunte, Ditte M. ; Skroza, Nevena ; Stergianou, Dimitra ; Szepietowski, Jacek ; Trigoni, Anastasia ; Vilarrasa, Eva ; van der Zee, Hessel H. / The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa : Results of a prospective European cohort study. I: Journal of the American Academy of Dermatology. 2021 ; Bind 85, Nr. 2. s. 369-378.

Bibtex

@article{e9787612cf3c4d18bbc36db624b393e2,
title = "The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study",
abstract = "Background: Tetracyclines and clindamycin plus rifampicin combination therapy are both considered first-line therapy in current hidradenitis suppurativa guidelines. However, evidence for their efficacy is drawn from small studies, often without validated outcomes. Objective: To assess the 12-week efficacy of oral tetracyclines and a combination of clindamycin and rifampicin. Methods: A prospective, international cohort study performed between October 2018 and August 2019. Results: In total, 63.6% of the included 283 patients received oral tetracyclines, and 36.4% were treated with clindamycin and rifampicin. Both groups showed a significant decrease in International Hidradenitis Suppurativa Severity Score System from baseline (both P < .001). The Hidradenitis Suppurativa Clinical Response (HiSCR) was achieved in 40.1% and 48.2% of patients, respectively (P = .26). Patient characteristics or disease severity were not associated with the attainment of HiSCR or the minimal clinically important differences for the Dermatology Life Quality Index and pain. Limitations: Cohort study. Respectively, 23.9% and 19.4% of patients had to be excluded from the HiSCR analysis for the tetracycline and combination therapy group because of a low abscess and nodule count at baseline. Conclusion: This study shows significant efficacy of both tetracycline treatment and clindamycin and rifampicin combination therapy after 12 weeks in patients with hidradenitis suppurativa. No significant differences in efficacy were observed between the 2 treatments, regardless of disease severity.",
keywords = "acne inversa, antibiotics, clindamycin, doxycycline, efficacy, guideline, minocycline, outcome, rifampicin, tetracycline, therapy, treatment",
author = "{van Straalen}, {Kelsey R.} and Thrasyvoulos Tzellos and Phillipe Guillem and Farida Benhadou and Carlos Cuenca-Barrales and Mathilde Daxhelet and Mathieu Daoud and Ourania Efthymiou and Giamarellos-Bourboulis, {Evangelos J.} and Jemec, {Gregor B.E.} and Katoulis, {Alexandros C.} and Anke Koenig and Elizabeth Lazaridou and Marzano, {Angelo V.} and {\L}ucas Matusiak and Alejandro Molina-Leyva and Chiara Moltrasio and Andreas Pinter and Concetta Potenza and Jorge Roman{\'i} and Saunte, {Ditte M.} and Nevena Skroza and Dimitra Stergianou and Jacek Szepietowski and Anastasia Trigoni and Eva Vilarrasa and {van der Zee}, {Hessel H.}",
note = "Publisher Copyright: {\textcopyright} 2021 American Academy of Dermatology, Inc.",
year = "2021",
doi = "10.1016/j.jaad.2020.12.089",
language = "English",
volume = "85",
pages = "369--378",
journal = "American Academy of Dermatology. Journal",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa

T2 - Results of a prospective European cohort study

AU - van Straalen, Kelsey R.

AU - Tzellos, Thrasyvoulos

AU - Guillem, Phillipe

AU - Benhadou, Farida

AU - Cuenca-Barrales, Carlos

AU - Daxhelet, Mathilde

AU - Daoud, Mathieu

AU - Efthymiou, Ourania

AU - Giamarellos-Bourboulis, Evangelos J.

AU - Jemec, Gregor B.E.

AU - Katoulis, Alexandros C.

AU - Koenig, Anke

AU - Lazaridou, Elizabeth

AU - Marzano, Angelo V.

AU - Matusiak, Łucas

AU - Molina-Leyva, Alejandro

AU - Moltrasio, Chiara

AU - Pinter, Andreas

AU - Potenza, Concetta

AU - Romaní, Jorge

AU - Saunte, Ditte M.

AU - Skroza, Nevena

AU - Stergianou, Dimitra

AU - Szepietowski, Jacek

AU - Trigoni, Anastasia

AU - Vilarrasa, Eva

AU - van der Zee, Hessel H.

N1 - Publisher Copyright: © 2021 American Academy of Dermatology, Inc.

PY - 2021

Y1 - 2021

N2 - Background: Tetracyclines and clindamycin plus rifampicin combination therapy are both considered first-line therapy in current hidradenitis suppurativa guidelines. However, evidence for their efficacy is drawn from small studies, often without validated outcomes. Objective: To assess the 12-week efficacy of oral tetracyclines and a combination of clindamycin and rifampicin. Methods: A prospective, international cohort study performed between October 2018 and August 2019. Results: In total, 63.6% of the included 283 patients received oral tetracyclines, and 36.4% were treated with clindamycin and rifampicin. Both groups showed a significant decrease in International Hidradenitis Suppurativa Severity Score System from baseline (both P < .001). The Hidradenitis Suppurativa Clinical Response (HiSCR) was achieved in 40.1% and 48.2% of patients, respectively (P = .26). Patient characteristics or disease severity were not associated with the attainment of HiSCR or the minimal clinically important differences for the Dermatology Life Quality Index and pain. Limitations: Cohort study. Respectively, 23.9% and 19.4% of patients had to be excluded from the HiSCR analysis for the tetracycline and combination therapy group because of a low abscess and nodule count at baseline. Conclusion: This study shows significant efficacy of both tetracycline treatment and clindamycin and rifampicin combination therapy after 12 weeks in patients with hidradenitis suppurativa. No significant differences in efficacy were observed between the 2 treatments, regardless of disease severity.

AB - Background: Tetracyclines and clindamycin plus rifampicin combination therapy are both considered first-line therapy in current hidradenitis suppurativa guidelines. However, evidence for their efficacy is drawn from small studies, often without validated outcomes. Objective: To assess the 12-week efficacy of oral tetracyclines and a combination of clindamycin and rifampicin. Methods: A prospective, international cohort study performed between October 2018 and August 2019. Results: In total, 63.6% of the included 283 patients received oral tetracyclines, and 36.4% were treated with clindamycin and rifampicin. Both groups showed a significant decrease in International Hidradenitis Suppurativa Severity Score System from baseline (both P < .001). The Hidradenitis Suppurativa Clinical Response (HiSCR) was achieved in 40.1% and 48.2% of patients, respectively (P = .26). Patient characteristics or disease severity were not associated with the attainment of HiSCR or the minimal clinically important differences for the Dermatology Life Quality Index and pain. Limitations: Cohort study. Respectively, 23.9% and 19.4% of patients had to be excluded from the HiSCR analysis for the tetracycline and combination therapy group because of a low abscess and nodule count at baseline. Conclusion: This study shows significant efficacy of both tetracycline treatment and clindamycin and rifampicin combination therapy after 12 weeks in patients with hidradenitis suppurativa. No significant differences in efficacy were observed between the 2 treatments, regardless of disease severity.

KW - acne inversa

KW - antibiotics

KW - clindamycin

KW - doxycycline

KW - efficacy

KW - guideline

KW - minocycline

KW - outcome

KW - rifampicin

KW - tetracycline

KW - therapy

KW - treatment

U2 - 10.1016/j.jaad.2020.12.089

DO - 10.1016/j.jaad.2020.12.089

M3 - Journal article

C2 - 33484766

AN - SCOPUS:85107160719

VL - 85

SP - 369

EP - 378

JO - American Academy of Dermatology. Journal

JF - American Academy of Dermatology. Journal

SN - 0190-9622

IS - 2

ER -

ID: 305554597